Italian guidelines and therapeutic algorithm for actinic keratoses

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 6, 2009, Pages 713-723

  Rossi, R ^a   Calzavara Pinton, P G ^b   Giannetti, A ^c   Peserico, A ^d   Santucci, M ^a   Vena, G A ^e   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

Guidelines as topic; Keratosis, actinic; Skin diseases, therapy

Indexed keywords

ALPHA2B INTERFERON; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; ISOTRETINOIN; RETINOID; TRICHLOROACETIC ACID;

ACTINIC KERATOSIS; ALGORITHM; CARBON DIOXIDE LASER; CARCINOGENESIS; CRYOTHERAPY; CURETTAGE; DISEASE COURSE; ERBIUM YAG LASER; EXCISION; FIELD CANCERIZATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENCE; ITALY; MALIGNANT TRANSFORMATION; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SUNLIGHT PROTECTION; THERMOCOAGULATION;

EID: 77949623861     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007;156:1-7.
2. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol 2007;46:895-904
3. Quatresooz P, Piérard-Franchimont C, Paquet P, Hubert P, Delvenne P, Pierard GE. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol 2008;18:6-10.
4. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(1 Pt 2):4-7.
5. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(1 Pt 2):8-10.
6. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006;155:9-22.
7. Braathen LR, Cerio R, Cribier B, Ferrandiz Foraster C, Giannetti A, Kemeny L et al. Subcommittee of the European Dermatology Forum. Guidelines for the Management of Actinic Keratoses. [cited 2009 October 9]. Available at: http://www.euroderm.org/.
8. Stockfleth E, Kerl H, Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006;16:599-606.
9. Ackerman AB. Solar keratosis is squamous cell carcinoma. Arch Dermatol 2003;139:1216-7.
10. Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000;43(1 Pt 1):138-50.
11. Rowert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007;156:8-12.
12. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998;139:1033-9.
13. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000;142:1154-9.
14. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:4-7.
15. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986;115:649-55.
16. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994;131:455-64.
17. Lewin Group, Inc. The Burden of Skin Diseases: 2004. Prepared for: The Society for invest. Derm. and The American Academy of Dermatology Association. Released April 2005.Copyright © 2005 by The Soc. for Invest. Derm. and The American Academy of Dermatology Association. [Accessed 2007 October 11; cited 2009 October 9]. Available at: http://www.sidnet.org/BurdenSkinDisease.asp
18. Naldi L, Chatenoud L, Piccitto R, Colombo P, Placchesi EB, La Vecchia C. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: results from the prevalence of actinic keratoses Italian study, 2003-2004. Arch Dermatol 2006;142:722-6.
19. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;12:403-6.
20. Jiang Y, Rabbi M, Kim M, Ke C, Lee W, Clark RL et al. UVA generates pyrimidine dimers in DNA directly. Biophys J 2009;96:1151-8.
21. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor protection. J Invest Dermatol Symp Proc 1996;1:136-42.
22. Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol 2003;139:876-82.
23. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2008;6:1066-9.
24. Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer treatment and prevention. Am J Clin Dermatol 2007;8:195-200.
25. Bianchini F, Massi D, Marconi C, Franchi A, Baroni G, Santucci M et al. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins Other Lipid Mediat 2007;83:320-8.
26. Higashi Y, Kanekura T, Kanzaki. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. T. Int J Cancer 2000;86:667-71.
27. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-92.
28. Fecker LF, Stockfleth E, Nondl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs) Br J Dermatol 2007;156:25-33.
29. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
30. Hiesse C, Kriaa F, Rieu P, Larue J, Benoit G, Bellamy J et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 1995;27:972-4.
31. McGregor J, Proby C. Skin cancer in transplant recipients. Lancet 1995;346:964-5.
32. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000;42:S11-S7.
33. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42(1 Pt 2):23-4.
34. Zamanian A, Mahjub H, Mehralian A. Skin diseases in kidney transplant recipients. Urol J 2006;3:230-3.
35. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, Baldan N, Alaibac M et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007;39:1847-50.
36. Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990;46:356-61.
37. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502.
38. Ulrich C, Christophers E, Sterry W, Meyer T, Stockfleth E. Skin diseases in organ transplant patients. Hautarzt 2002;53:524-33.
39. Jorizzo J, Stewart D, Bucko A, Davis SA, Espy P, Hino P et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-,2-,or 4-week treatment in patients with actinic keratosis. Cutis 2002;10:335-9.
40. Actinic keratosis. In: Habif T, editors. Clinical dermatology. 4th ed. St. Louis, MO: Mosby-Yearbook, Inc.; 2004. p. 736-43.
41. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
42. Braakhuis BJ, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention?. Oncologist 2005;10:493-500.
43. Braakhuis BJ, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol 2005;15:113-20.
44. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res 2003;63:1727-30.
45. Reichrath J, Querings K. Histology of epithelial skin tumors. In: Olson MOJ, editor. The Nucleolus. Austin, TX: Landes Bioscience; 2004.
46. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H for the European Skin Academy. Development of a treatment algorithm for actinic Keratoses: a European Consensus. Eur J Dermatol 2008;18:651-9.
47. Stern RS, Bolshakov S, Nataraj AJ, Ananthaswamy HN. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol 2002;119:522-6.
48. Ostertag JU, Quaedvlieg PJ, van der Geer S, Nelemans P, Christianen ME, Neumann MH et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med 2006;38:731-9.
49. Castineiras I, Del Pozo J, Mazaira M, Rodriguez-Lojo R, Fonseca E. Actinic cheilitis: evolution to squamous cell carcinoma after carbon dioxide laser vaporization. A study of 43 cases. J Dermatolog Treat 2009;1:1-5.
50. Chiarello SE. Radiovaporization: radiofrequency cutting current to vaporize and sculpt skin lesions. Dermatol Surg 2003;29:755-8.
51. Brown MB, Marriott C, Martin GP. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int J Tissue React 1995;17:133-40.
52. Moore AR, Willoughby DA. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 1995;17:153-6.
53. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;40:709-13.
54. Rivers JK, Wolf J. Assessing clinically meaningful end points for the management of actinic keratoses with diclofenac 3% gel. Acta Derm Venereol 2007;87:188-9.
55. Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. Skin Therapy Lett 2004;9:1-3.
56. Gebauer K, Brown P, Arigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003;44:40-3.
57. Patel MJ, Stockfleth E. Does progression from actinic keratosis and Bowen's disease end with treatment:diclofenac 3% gel, an old drug in a new environment? Br J Dermatol 2007;156:53-6.
58. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002;47:258-62.
59. Foley PJ. Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. Dermatolog Treat 2003;14:15-22.
60. Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:227-32.
61. Berman B, Sullivan T, De Araujo T, Nadji M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003;149:59-61.
62. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol 2002;47:571-7.
63. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. Am Acad Dermatol 2004;50:714-21.
64. Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55.
65. Benson E. Imiquimod: potential risk of an immunostimulant. Austral J Derm 2004;45:123-4.
66. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005;141:985-93.
67. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, Van de Kerkhof PC et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients 1. Br J Dermatol 2007;157:25-31.
68. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs. 5% fluorouracil in the treatment of widespread facial actinic keratosis. Dermatol Surg 1997;23:191-6.
69. Sander CA, Pfeiffer C, Kligmann AM, Plewig G. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 1997;36:236-8.
70. Edwards L. The interferons. Dermatol Clin 2001;19:139-46.